Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YZJ-1139 in Insomnia Disorder
NCT06975514Phase 3Completed
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fazamorexant in insomnia disorder (2 arms), sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Primary endpoints: Objective Wake After Sleep Onset, Objective Sleep Efficiency and 2 more. Started Mar 2025; status: completed.
02
Drugs
fazamorexant
03
Conditions
insomnia disorder
Beyond the preview
Go deeper on NCT06975514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975514.